- 1
- 2
- 3
- 4
A New Model For A New Era Of Psychedelic Therapy
- 1
- 2
- 3
- 4
Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma’s CEO Bruce Cozadd
- 1
- 2
- 3
- 4
Thinking Differently About Rare Disease Therapies
- 1
- 2
- 3
- 4
A Q&A With A Venture Capitalist/Genetic Medicines Executive
ALSO IN THIS MONTH'S ISSUE
-
![Future of Life Sciences Industry_450x300]( "The Future Of The Life Sciences Industry And What You Need To Know")
The Future Of The Life Sciences Industry And What You Need To KnowThe industry must now prepare to respond to multiple converging trends — some new and some old — but all profoundly affected by the COVID-19 pandemic and in the coming post-pandemic environment.
-
![CtW - Castle Creek_450x300]( "Companies To Watch: Castle Creek Biosciences")
Companies To Watch: Castle Creek BiosciencesFor Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.
-
![platforms to pipelines_450x300 (002)]( "Platforms To Pipelines: Part 2")
Platforms To Pipelines: Part 2In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.
-
![Medical Affairs at Product Launch_450x300]( "Is A Key Function To Product Launch Excellence Being Overlooked?")
Is A Key Function To Product Launch Excellence Being Overlooked?Learn how medical affairs can help propel product launches for highly complex therapies.
BEYOND THE PRINTED PAGE
-
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
-
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
-
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
MAY 2022 DIGITAL EDITION
LIFE SCIENCE LEADER CONTENT COLLECTIONS
2022 CMO & CRO AWARDS EDITION
ASK THE BOARD
- How Can I Prepare To Join And Serve On A Board Of Directors?
- How Can Digital Technology Improve The Treatment Of Neurological Disorders?
- Following The Approval Of Biogen’s Aduhelm, There Has Been Talk About “Reining In” The FDA’s Accelerated Approval Pathway. How Important Is Accelerated Approval For Rare Disease Drugs?